Dystonia Clinical Research in 2026: The Stride Study of VIM0423 at INWR

By: Michael Dauer, MS, MBA

Research Director, Inland Northwest Research

Dystonia is one of the most under-recognized movement disorders in neurology. It affects a large number of individuals in the United States, yet many patients wait years between the onset of symptoms and an accurate diagnosis. For the subset of patients with isolated dystonia — where dystonia is the primary neurological symptom rather than part of a broader condition — treatment has largely focused on symptom management, including botulinum toxin injections, off-label oral medications, or, in selected cases, deep brain stimulation surgery.

That is beginning to change. In 2026, a new generation of research is exploring whether dystonia's underlying biology can be addressed more directly — with an oral therapy taken at home rather than an injection delivered every three months. Inland Northwest Research (INWR) in Spokane is currently enrolling participants for a clinical trial evaluating this approach.

The Science of 2026: Rebalancing the Cholinergic System

The scientific rationale driving current dystonia research centers on neurotransmitter balance in the brain. In healthy motor control, dopamine and acetylcholine operate as counterbalancing signals. When dopamine signaling is reduced or otherwise disrupted, acetylcholine activity may become relatively unopposed, contributing to abnormal motor signaling.

This relative imbalance in cholinergic signaling is an area of active research and is believed to play a role across several movement disorders, including dystonia and Parkinson's disease. Drugs that block muscarinic acetylcholine receptors are not new. Trihexyphenidyl, for example, has been used for decades in movement disorders.

The challenge has historically been tolerability. Older anticholinergic drugs act broadly across the central and peripheral nervous systems, producing side effects such as dry mouth, blurred vision, constipation, urinary retention, and cognitive slowing. These effects have often limited long-term use, even when the underlying mechanism may provide benefit. A key question in current research is whether new muscarinic targeting can provide clinical benefit while improving tolerability.

What the Science Has Delivered So Far

The path to current studies was built on early-phase clinical research. Vima Therapeutics, a biotechnology company based in Cambridge, Massachusetts, has developed VIM0423 and conducted Phase 1 studies evaluating pharmacokinetics, safety, tolerability, and dose titration in both healthy volunteers and individuals living with dystonia.

In these Phase 1 studies, VIM0423 was reported to be safe and well tolerated at and above the intended exposure range over a 28-day dosing period. These results supported advancement into Phase 2 clinical trials and contributed to continued investment in the program.

In March 2026, the first participant was dosed in the Phase 2 Stride Dystonia study. The FDA has granted VIM0423 Fast Track designation for the treatment of isolated dystonia, a regulatory status intended to help accelerate development for serious conditions with unmet medical need.

For the dystonia community, these are meaningful signals. They do not establish that VIM0423 is effective — that is precisely what Phase 2 studies are designed to determine. However, they do reflect continued progress in developing therapies that aim to target underlying disease mechanisms.

The Stride Dystonia Study at INWR (VIM0423-201)

INWR is currently enrolling for the Stride Dystonia study, a Phase 2, randomized, double-blind, placebo-controlled trial evaluating VIM0423 in individuals with isolated dystonia. The study (ClinicalTrials.gov identifier NCT07304089) is designed to evaluate whether the investigational therapy improves symptoms, is well tolerated, and contributes to meaningful changes in daily function and quality of life. Additional information about the study is available at stridedystonia.com.

VIM0423 is an investigational oral therapy designed to target muscarinic cholinergic signaling, with the goal of addressing central mechanisms while improving tolerability compared to older medications. Participants in the study are randomized in a 1:1 ratio to receive either VIM0423 or placebo. Because the study is double-blind, neither the participant nor the study team knows which assignment an individual has received until the blinded portion of the study is complete. This design is essential for producing reliable and interpretable results, particularly in conditions where symptom reporting and clinical assessment both play important roles.

Topline data from the Stride Dystonia study, along with a separate Phase 2 study of VIM0423 in Parkinson's disease expected to begin in 2026, are anticipated in the first half of 2027. The study is evaluating adults ages 18 to 65 with isolated dystonia. Additional eligibility criteria apply, and final determination is made during a formal screening process at the study site. Because each clinical trial has specific inclusion and exclusion criteria, individuals with other forms of dystonia or additional neurological conditions may or may not qualify.

If you are between ages 18 and 65 and have been diagnosed with isolated dystonia, you may be eligible for the Stride Dystonia study. Contact INWR at (509) 960-2818 or contact@inwresearch.com to begin the pre-screening process, or visit stridedystonia.com to learn more about the study.

Why Heterogeneity Matters in Dystonia Research

From a clinical and research perspective, dystonia is not a single disease but a group of related movement patterns. The term describes involuntary, sustained, or repetitive muscle contractions, but the underlying causes, distribution, and clinical course can vary significantly between individuals.

Clinicians and researchers often describe dystonia based on how it presents in the body. It may be focal, affecting a single region such as the neck or eyelids; segmental, involving adjacent regions; multifocal, involving non-adjacent regions; or generalized, involving the trunk and multiple additional areas.

Dystonia is also categorized based on whether it occurs in isolation or as part of a broader neurological condition. Some forms have identified genetic causes, while others are considered idiopathic, meaning no specific cause has been established.

These distinctions are important in clinical research. Studies are designed to evaluate therapies in specific patient populations where the underlying biology and clinical presentation are most closely aligned with the investigational approach.

How Participation Advances the Field

Clinical research in dystonia depends on patient participation. Because dystonia is relatively uncommon and highly variable in presentation, studies require carefully selected participants whose clinical characteristics align with the study design.

Participation helps answer fundamental scientific questions, including whether a new therapeutic approach provides meaningful benefit, how outcomes should be measured, and how future studies should be designed. Even in placebo-controlled trials, every participant contributes to the data needed to advance understanding of the condition.

About Clinical Research at Inland Northwest Research

Inland Northwest Research actively participates in clinical research across a range of movement disorders, including dystonia, Parkinson's disease, Multiple System Atrophy, Huntington's disease, and Essential Tremor. The research portfolio evolves over time as new studies become available.

New research opportunities are shared after appropriate regulatory approvals are in place and studies are open for enrollment. Patients, caregivers, and referring clinicians are encouraged to reach out to learn more about current or future opportunities.

Research vs. Treatment: An Important Distinction

Inland Northwest Research is a clinical trial site, not a primary care clinic. Selkirk Neurology provides established medical care and treatment for movement disorders under the direction of Dr. Jason Aldred. INWR conducts regulated clinical studies designed to evaluate investigational therapies.

In clinical trials such as Stride Dystonia, participants are randomized, and some receive placebo as part of the study design. This is a necessary component of determining whether a treatment is safe and effective. There is no guarantee of direct medical benefit to individual participants.

Participation is entirely voluntary, and individuals may withdraw at any time without penalty or effect on their medical care. Eligibility criteria, visit schedules, risks, and potential compensation vary by protocol. All of these details are reviewed thoroughly during the informed consent process, which occurs before any research activities begin.

Participants are encouraged to review consent documents with family members and their treating neurologist before making any decision.

How the Enrollment Process Works

For any study at INWR, the enrollment process follows the same structured steps designed to protect participants and ensure the right fit between individual and protocol:

Connect. Reach out to us at (509) 960-2818 or contact@inwresearch.com.

Pre-Screen. We review medical history and basic eligibility criteria specific to each protocol.

Informed Consent Review. If preliminarily eligible, you will receive a detailed informed consent form to review before making any decision.

For more information on the Stride Dystonia study specifically, visit stridedystonia.com or the study's listing on ClinicalTrials.gov (NCT07304089).